1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Change in number of shares and votes in SynAct Pharma

LHFI

During the month of December, the number of shares and votes in SynAct Pharma AB (publ) have increased due to a directed issue of shares which was resolved upon by the board of directors on December 12, 2022, pursuant to the authorization granted by the annual general meeting on May 20, 2022.

Through the direct share issue, carried out in December 2022, the number of outstanding shares and votes has increased by 1,277,954, from 28,370,503 to 29,648,457. The share capital has increased by SEK 159,744.25, from SEK 3,546,312.875 to SEK 3,706,057.125.

As of December 30, 2022, the total number of shares and votes in SynAct Pharma AB amounts to 29,648,457 shares and votes.

For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com              
 
Patrik Renblad
CFO, SynAct Pharma AB 
Phone: +46 707 47 97 68 
Mail: par@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com. 

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-12-30 13:00 CET.

Attachments
Change in number of shares and votes in SynAct Pharma

Datum 2022-12-30, kl 13:00
Källa MFN
Bifogade filer
Change in number of shares and votes in SynAct Pharma
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!